THE CONCOMITANT DETERMINATION OF DIFFERENT TUMOR-MARKERS IN PATIENTS WITH EPITHELIAL OVARIAN-CANCER AND BENIGN OVARIAN MASSES - RELEVANCE FOR DIFFERENTIAL-DIAGNOSIS

被引:102
作者
GADDUCCI, A
FERDEGHINI, M
PRONTERA, C
MORETTI, L
MARIANI, G
BIANCHI, R
FIORETTI, P
机构
[1] UNIV PISA,DEPT OBSTET & GYNECOL,I-56100 PISA,ITALY
[2] UNIV PISA,DEPT NUCL MED,I-56100 PISA,ITALY
[3] UNIV PISA,MED CLIN 2,I-56100 PISA,ITALY
关键词
D O I
10.1016/0090-8258(92)90030-M
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The serum levels of CA 125 (cutoff limit, 65 U/ml), CA19.9 (cutoff, 40 U/ml), CA 15.3 (cutoff, 32 U/ml), CA72.4 (cutoff, 3.8 U/ml), and TATI (cutoff, 22 ng/ml) were preoperatively measured in 90 patients with epithelial ovarian cancer and in 254 patients with benign ovarian pathology. CA125 had a sensitivity of 75.6%, a specificity of 86.6%, and a diagnostic accuracy of 83.7% for epithelial ovarian cancer; CA19.9 had a sensitivity of 35.6%, a specificity of 81.1%, and a diagnostic accuracy of 69.2%; CA15.3 had a sensitivity of 57.1%, a specificity of 93.9%, and a diagnostic accuracy of 84.6%; CA72.4 had a sensitivity of 70.7%, a specificity of 91.8%, and a diagnostic accuracy of 86.2%; and TATI had a sensitivity of 47.3%, a specificity of 95.3%, and a diagnostic accuracy of 82.9%. CA 125 was the most sensitive marker for nonmucinous tumors, while CA19.9 and CA72.4 were the antigens more frequently expressed by mucinous malignancies. The sensitivities of serum CA 125 (81.1% vs 50.0%; P = 0.01) and TATI (55.2% vs 18.8%; P = 0.02) were higher in patients above 50 years of age than in younger patients while specificities were quite similar in both age groups. The association of serum CA125 and CA19.9 had a significantly higher sensitivity (93.2% vs 81.1%; P = 0.03) and a slightly lowered specificity (78.9% vs 86.0%; P = 0.46) than CA125 assay alone in the differential diagnosis of ovarian masses in patients above 50 years of age. © 1992.
引用
收藏
页码:147 / 154
页数:8
相关论文
共 35 条
  • [1] A RADIOIMMUNOASSAY USING A MONOCLONAL-ANTIBODY TO MONITOR THE COURSE OF EPITHELIAL OVARIAN-CANCER
    BAST, RC
    KLUG, TL
    STJOHN, E
    JENISON, E
    NILOFF, JM
    LAZARUS, H
    BERKOWITZ, RS
    LEAVITT, T
    GRIFFITHS, CT
    PARKER, L
    ZURAWSKI, VR
    KNAPP, RC
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1983, 309 (15) : 883 - 887
  • [2] REACTIVITY OF A MONOCLONAL-ANTIBODY WITH HUMAN OVARIAN-CARCINOMA
    BAST, RC
    FEENEY, M
    LAZARUS, H
    NADLER, LM
    COLVIN, RB
    KNAPP, RC
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1981, 68 (05) : 1331 - 1337
  • [3] MONITORING HUMAN OVARIAN-CARCINOMA WITH A COMBINATION OF CA-125, CA-19-9, AND CARCINOEMBRYONIC ANTIGEN
    BAST, RC
    KLUG, TL
    SCHAETZL, E
    LAVIN, P
    NILOFF, JM
    GREBER, TF
    ZURAWSKI, VR
    KNAPP, RC
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1984, 149 (05) : 553 - 559
  • [4] CA19-9 AS A MARKER FOR OVARIAN-CANCER - ALONE AND IN COMPARISON WITH CA125
    CANNEY, PA
    WILKINSON, PM
    JAMES, RD
    MOORE, M
    [J]. BRITISH JOURNAL OF CANCER, 1985, 52 (01) : 131 - 133
  • [5] CARCINOEMBRYONIC ANTIGEN (CEA) AND CARBOHYDRATE DETERMINANT 19-9 (CA 19-9) LOCALIZATION IN 121 PRIMARY AND METASTATIC OVARIAN-TUMORS - AN IMMUNOHISTOCHEMICAL STUDY WITH THE USE OF MONOCLONAL-ANTIBODIES
    CHARPIN, C
    BHAN, AK
    ZURAWSKI, VR
    SCULLY, RE
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 1982, 1 (03) : 231 - 245
  • [6] TUMOR-MARKERS IN GYNECOLOGIC ONCOLOGY
    DAUNTER, B
    [J]. GYNECOLOGIC ONCOLOGY, 1990, 39 (01) : 1 - 15
  • [7] EINHORN N, 1986, OBSTET GYNECOL, V67, P414
  • [8] FINKLER NJ, 1988, OBSTET GYNECOL, V72, P659
  • [9] CORRELATION OF CA125 AND CA19-9 SERUM LEVELS WITH CLINICAL COURSE AND 2ND-LOOK FINDINGS IN PATIENTS WITH OVARIAN-CARCINOMA
    FIORETTI, P
    GADDUCCI, A
    FERDEGHINI, M
    BARTOLINI, T
    BIANCHI, R
    FACCHINI, V
    [J]. GYNECOLOGIC ONCOLOGY, 1987, 28 (03) : 278 - 283
  • [10] GION M, 1986, J NUCL MED ALLIED S, V30, P29